© 2023 MJH Life Sciences™ and Cannabis Patient Care. All rights reserved.
A study published in January 2023 examined the effects of high and low doses of cannabigerol (CBG) on mice liver.
Cannabigerol (CBG) may have therapeutic potential when treating nonalcoholic fatty liver disease (NAFLD), concluded a study published by researchers at the Universities of Utah and Northern Colorado (1). The study, published in MDPI in the Special Issue "Liver Disease, Lifestyle and Cardiovascular Risk,” analyzed the effects of CBG on hepatic steatosis, fibrosis, and inflammation connected to NAFLD (1). Scientists analyzed the livers of mice after being separated into groups, fed specific diets, then given either low or high doses of CBG.
“Overall, our results suggest that the low dose of CBG treatment has a higher potential for alleviating liver damage due to methionine/choline-deficient (MCD)-induced non-alcoholic steatohepatitis (NASH) symptoms, compared to high dose of CBG, which caused elevated liver damage,” read part of the study’s results section (2). “In conclusion, this study provides initial findings and a foundation for future studies on the efficacy of CBG on NASH.”
CBG is called “The Mother Cannabinoid” because all other cannabinoids derive from it. CBG also has potential anti-inflammatory effects similar to other cannabinoids and is non-psychotropic (1,2).